Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bio-Rad Laboratories (BIO) ...

The average one-year price target for Bio-Rad Laboratories (NYSE:BIO) has been revised to $362.10 / share. This is an increase of 14.15% from the prior estimate of $317.22 dated November 7, 2025. The ...

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Bio-Rad Laboratories is starting to look ...

Bio-Rad Laboratories, Inc.’s BIO Clinical Diagnostics business is back to its usual growth trajectory post-pandemic while maintaining a strong market position worldwide for key platforms. The ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -5.14% in ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...